REVIEW ON COST EFFECTIVENESS OF SHINGLES VACCINE

NOTICE PAPER NO. 3219

NOTICE OF QUESTION FOR ORAL ANSWER

FOR THE SITTING OF PARLIAMENT ON OR AFTER 12 NOVEMBER 2024

Name and Constituency of Member of Parliament

Dr Christoper de Souza

MP for Holland-Bukit Timah GRC

Question No. 6860

To ask the Minister for Health (a) whether the review of the cost effectiveness of shingles vaccine has been completed; and (b) if so, whether the Ministry will add it to the National Adult Immunisation Schedule such that it will be eligible for subsidies, especially for vulnerable seniors.

Answer

The review of the cost effectiveness of the shingles vaccine, Shingrix, has been completed. At the price proposed by the manufacturer, the vaccine is not considered cost-effective for the prevention of shingles at the population level. We will continue to discuss with the manufacturer and monitor their pricing.